PharmaRoth Labs (PharmaRoth Labs) Change In Receivables : $0.00 Mil (TTM As of Mar. 2011)

View and export this data going back to 2008. Start your Free Trial

What is PharmaRoth Labs Change In Receivables?

PharmaRoth Labs's change in receivables for the quarter that ended in Mar. 2011 was $0.00 Mil. It means PharmaRoth Labs's Accounts Receivable stayed the same from Dec. 2010 to Mar. 2011 .

PharmaRoth Labs's change in receivables for the fiscal year that ended in Jun. 2010 was $0.00 Mil. It means PharmaRoth Labs's Accounts Receivable stayed the same from Jun. 2009 to Jun. 2010 .

PharmaRoth Labs's Accounts Receivable for the quarter that ended in Mar. 2011 was $0.10 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PharmaRoth Labs's Days Sales Outstanding for the three months ended in Mar. 2011 was 43.34.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PharmaRoth Labs's liquidation value for the three months ended in Mar. 2011 was $-0.32 Mil.

PharmaRoth Labs Change In Receivables Historical Data

The historical data trend for PharmaRoth Labs's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaRoth Labs Change In Receivables Chart

PharmaRoth Labs Annual Data

Trend

Jun08

Jun09

Jun10

Change In Receivables

PharmaRoth Labs Quarterly Data
	Mar07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
Change In Receivables	Get a 7-Day Free Trial											-	-	-	-	-

PharmaRoth Labs Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PharmaRoth Labs (GREY:ROTH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PharmaRoth Labs's Days Sales Outstanding for the quarter that ended in Mar. 2011 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.095	/	0.2	*	91
=	43.34

2. In Ben Graham's calculation of liquidation value, PharmaRoth Labs's accounts receivable are only considered to be worth 75% of book value:

PharmaRoth Labs's liquidation value for the quarter that ended in Mar. 2011 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0	-	0.39	+	0.75 * 0.095	+	0.5 * 0
=	-0.32

PharmaRoth Labs Change In Receivables Related Terms

Thank you for viewing the detailed overview of PharmaRoth Labs's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaRoth Labs (PharmaRoth Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaRoth Labs Inc (GREY:ROTH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

8250 West Charleston Boulevard, Suite 110, Las Vegas, NV, USA, 89117

Website

http://www.pharmaroth.com

PharmaRoth Labs Inc is engaged in the manufacture and sale of a treatment for Type II diabetes called Sucanon. The company also does marketing and selling of nutraceutical drugs.

PharmaRoth Labs (PharmaRoth Labs) Headlines

From GuruFocus

Hotchkis and Wiley Value Opportunities Fund Buys Rothschild SCA, Oracle Corp, Medtronic PLC, Sells Amerco Inc, Anthem Inc, F5 Inc

By GuruFocusNews insider • 03-29-2022